Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 68Carcinoma, Non-Small-Cell Lung 64Multiple Myeloma 52Prostatic Neoplasms 47Colorectal Neoplasms 40Leukemia, Myeloid, Acute 39Neoplasms 35Melanoma 31Lymphoma 31Ovarian Neoplasms 29Lymphoma, Non-Hodgkin 28Sarcoma 27Lung Neoplasms 26Squamous Cell Carcinoma of Head and Neck 24Neoplasm Metastasis 24Carcinoma, Hepatocellular 24Pancreatic Neoplasms 22Endometrial Neoplasms 22Hodgkin Disease 21Glioma 21Recurrence 20Leukemia, Lymphocytic, Chronic, B-Cell 20Carcinoma, Renal Cell 20Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Urinary Bladder Neoplasms 18Myelodysplastic Syndromes 18Lymphoma, Large B-Cell, Diffuse 18Head and Neck Neoplasms 18Rectal Neoplasms 15Hematologic Neoplasms 15

Interventions

cemiplimab 1Pemetrexed 1Paclitaxel 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Resectable Non-small Cell Lung Cancer × 30 days × Clear all
NCT06161441 2026-05-28

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
195 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡